Abstract
Alzheimer’s disease (AD) is considered the main cause of dementia in Western countries. Consequently, there is a need for an accurate, universal, specific and cost-effective biomarker for early AD diagnosis, to follow disease progression and therapy response. This article describes a new diagnostic approach to quantitative electroencephalogram (QEEG) diagnosis of mild and moderate AD. The data set used in this study was composed of EEG signals recorded from 2 groups: (S1) 74 normal subjects, 33 females and 41 males (mean age 67 years, standard deviation = 8) and (S2) 88 probable AD patients (NINCDS-ADRDA criteria), 55 females and 33 males (mean age 74.7 years, standard deviation = 7.8) with mild to moderate symptoms (
Get full access to this article
View all access options for this article.
